Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.50 |
| ▸ | CTSD | P07339 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863316 | 1.00 | TRPM8 (0.53) | TRPM8BACE1CTSDCTSBCTRB1 | |
| SCHEMBL2582361 | 0.86 | SPPL2A (0.53) | TRPM8BACE1CTSDCTSBCTRB1 | |
| SCHEMBL2577831 | 0.86 | SPPL2A (0.53) | TRPM8BACE1CTSDCTSBCTRB1 | |
| SCHEMBL4908808 | 0.86 | SPPL2A (0.53) | TRPM8BACE1CTSDCTSBCTRB1 | |
| SCHEMBL6888172 | 0.86 | BACE1 (0.51) | BACE1CTSDBCHE | |
| SCHEMBL7614119 | 0.86 | BACE1 (0.51) | BACE1CTSDBCHE | |
| SCHEMBL7614124 | 0.86 | BACE1 (0.51) | BACE1CTSDBCHE | |
| SCHEMBL7761083 | 0.85 | KLK5 (0.57) | BACE1CTSSBCHECTSK | |
| SCHEMBL5379746 | 0.85 | KLK5 (0.57) | BACE1CTSSBCHECTSK | |
| SCHEMBL5379743 | 0.85 | KLK5 (0.57) | BACE1CTSSBCHECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-7045518-B2 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040267022-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2004-12-30 | — | — | US | disclosed |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1052250-B1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | SEARLE & CO (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6743929-B1 | AMINO AND N-AMINO PROTECTED EPOXIDE INTERMEDIATES | G. D. SEARLE & CO. | 2004-06-01 | — | — | US | disclosed |
| US-6667307-B2 | HIV protease | G.D. SEARLE & CO. | 2003-12-23 | — | — | US | disclosed |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | disclosed |
| US-6380188-B1 | FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS PROTEASE | G. D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0813519-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2001-05-09 | — | — | EP | disclosed |
| US-5760064-A | RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0656888-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5705500-A | HIV TREATMENT | G.D. SEARLE & CO. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0813519-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5639769-A | ADMINISTERING ANTIVIRAL AGENT | G.D. SEARLE AND CO. (US) | 1997-06-17 | — | — | US | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5521219-A | TREATMENT OF AIDS | G. D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5510388-A | TREATING HTLV, AIDS | G. D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508294-A | USED TO TREAT HIV INFECTION | G.D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1994004493-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267022-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, PRSS1, TMPRSS15 | TRPM8 3976/4885BACE1 241/4885CTSD 60/4885 |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | TRPM8 3514/4885BACE1 122/4885CTSD 37/4885 |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | TRPM8 3514/4885BACE1 122/4885CTSD 37/4885 |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | TRPM8 3514/4885BACE1 122/4885CTSD 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.